Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H31NO.C4H4O4 |
Molecular Weight | 417.5384 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C3=CC=CC=C3
InChI
InChIKey=RFQWRWCCNQNACG-HJYQBBATSA-N
InChI=1S/C20H31NO.C4H4O4/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16;5-3(6)1-2-4(7)8/h6-10,17H,11-15H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t17-,19-,20+;/m1./s1
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | C20H31NO |
Molecular Weight | 301.4662 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. | 2001 Jan |
|
Deramciclane (Egis). | 2002 Feb |
|
Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds. | 2002 Mar |
|
In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers. | 2002 Mar |
|
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. | 2003 |
|
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. | 2003 Dec |
|
Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats. | 2004 Apr |
|
Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. | 2004 Aug |
|
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. | 2004 Feb |
|
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. | 2005 Dec |
|
Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human. | 2005 Nov |
|
Role of CYP2E1 in deramciclane metabolism. | 2005 Nov |
|
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. | 2008 Jan |
|
Deramciclane improves object recognition in rats: potential role of NMDA receptors. | 2010 Feb |
|
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein. | 2010 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15949921
60 mg/day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:41 GMT 2023
by
admin
on
Fri Dec 15 15:25:41 GMT 2023
|
Record UNII |
W1183TY0EE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
W1183TY0EE
Created by
admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
|
PRIMARY | |||
|
6438165
Created by
admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
|
PRIMARY | |||
|
120444-72-6
Created by
admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
|
PRIMARY | |||
|
m4186
Created by
admin on Fri Dec 15 15:25:41 GMT 2023 , Edited by admin on Fri Dec 15 15:25:41 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |